The abstract is read at the publisher; the summary is JClub's.
An ex vivo live tumor fragment platform using standard-of-care biopsies predicts ICI response with an elive index AUC of 0.99 by cytokine changes between IgG and treatment phases.
- Why it matters: Functional assays can predict immune checkpoint inhibitor response but are hard to scale because they require manual processing of large resections at academic centers.
- What they did: In prospective multicenter observational studies, live tumor fragments from 228 patients were assayed ex vivo, and hierarchical clustering of cytokine production changes defined responder versus nonresponder groups.
- The result: The elive index matched clinical benefit in 93% (26/28) of patients (p = 3.2 × 10−5) and identified 83% (10/12) of objective responders, including among biomarker-negative patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.